Atici A E, Bostanci E B, Ozer I, Ulas M, Akdogan M, Akoglu M
Department of Gastrointestinal Surgery, Kartal Kosuyolu Yuksek Ihtisas Teaching and Research Hospital.
Transplant Proc. 2011 Apr;43(3):909-11. doi: 10.1016/j.transproceed.2010.11.019.
Early postoperative infections are one of the major causes of morbidity and mortality following orthotopic liver transplantation. The severity of these infections may be increased in patients with neutropenia. There are no guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for the treatment of neutropenia in posttransplant liver recipients. However, it has been recommended by several authors. We have herein presented two patients who were treated effectively with G-CSF. Both patients developed severe neutropenia (<500/mm(3)) on the third postoperative day, and received intravenous G-CSF administration for 3 days. The neutrophil counts gradually increased and additional infusions were not needed. The immunosuppressive and prophylactic treatments were not altered. G-CSF administration was used effectively for 3 days in our two patients. No evidence of infectious or acute rejection episode was encountered during or following G-CSF treatment.
术后早期感染是原位肝移植后发病和死亡的主要原因之一。中性粒细胞减少的患者这些感染的严重程度可能会增加。目前尚无关于使用粒细胞集落刺激因子（G-CSF）治疗肝移植受者中性粒细胞减少的指南。然而，几位作者已推荐使用。我们在此报告了两名接受G-CSF有效治疗的患者。两名患者均在术后第三天出现严重中性粒细胞减少（<500/mm³），并接受了3天的静脉注射G-CSF治疗。中性粒细胞计数逐渐增加，无需额外输注。免疫抑制和预防性治疗未改变。G-CSF在我们的两名患者中有效使用了3天。在G-CSF治疗期间或之后未发现感染或急性排斥反应的证据。
